HTB South

Paediatric care

Stopping treatment after early ART in infants

Delaying ART in childhood can reduce long-term CD4 count in adulthood

Efavirenz under-dosing in children

Treatment response and duration of first line treatment in European infants

Pharmacokinetics of paediatric tenofovir based regimens

Atazanavir pharmacokinetics in infants, children and adolescents

Crushing lopinavir/ritonavir tablets decreases exposure by almost half in children

No difference in AIDS-free survival in children starting ART with a CD4% between 15%–24% compared to deferring until less than 15% in the PREDICT trial

Paediatric antiretroviral pipeline: update on etravirine and maraviroc

More metabolic abnormalities in children receiving a PI compared to NNRTI in NEVEREST study

Prematurity not associated with early mortality in infants on ART

Treating children previously exposed to single dose nevirapine: update on IMPAACT P1060 and NEVEREST

Lopinavir/ritonavir oral solution toxicity in neonates

Paediatric antiretroviral pipeline: darunavir and raltegravir

Long-term outcomes for infants starting lopinavir/ritonavir at less than 6 months

Effects of antiretroviral exposure through PMTCT strategies on infants in Botswana

Pharmacokinetics of lopinavir/ritonavir in combination with rifampicin based TB treatment in children

New WHO guidelines for children

Initiating nevirapine with fixed dose combination “mini-pills” in Zambia

Daily cotrimoxazole preferable to intermittent preventative therapy in HIV-infected children

Pilot PK study of two generic paediatric formulations of lopinavir/ritonavir vs originator products

HIV, the brain and children

Treating children previously exposed to single dose nevirapine

Phenotypic and genotypic inhibitory quotients and virologic response in treatment experienced children

Pharmacokinetic studies in very young infants

Double-dose lopinavir/ritonavir provides insufficient lopinavir exposure in children receiving rifampicin

PI-based ART in HIV-infected and HIV/TB coinfected children in South Africa

Children on HAART do extremely well at South African clinic

Etravirine dose selection in children aged 6 to 17

Preliminary results from first paediatric raltegravir study

Inflammation and coagulation markers askew in children with higher HIV RNA

Initial results from PENTA 11 trial of planned treatment interruptions

Dosing of lopinavir/ritonavir in the CHIPS cohort

Lack of efficacy of isoniazid (INH) prophylaxis and PK evaluation in South African infants

48-week data for darunavir/ritonavir (DRV/r) in treatment-experienced children and adolescents

New paediatric formulations of ARVs

FDA approves new paediatric AZT dosing

Antiretroviral therapy in HIV-positive children in Southern Africa

Immune reconstitution inflammatory syndrome in young children initiating ART

Complications with BCG vaccination in HIV-positive and negative infants: CHER Study

The association between clinical characteristics and HIV-infection in very young infants

Paediatric pharmacokinetic studies

NNRTI resistance in infants prophylaxed with single-dose nevirapine varies by the timing of infection

Post navigation